| Project/Area Number |
15K20574
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Osaka Dental University |
|---|
Principal Investigator |
TSUJI Kaname 大阪歯科大学, 歯学部, 助教 (80632083)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | Vγ9Vδ2T細胞 / 口腔癌 / 口腔癌細胞 / γδT細胞 |
|---|
| Outline of Final Research Achievements |
Vγ9Vδ2 T cells, the major subset of the human peripheral blood γδ T-cell, respond to microbial infection and stressed cells through the recognition of phosphoantigens. Vγ9Vδ2 T cells kill a broad range of tumors, including breast cancers, colon carcinomas, lymphomas, melanomas, myelomas, and prostate cancers. However, there has not been an examination of whether Vγ9Vδ2 T cells would target oral carcinomas. We demonstrated that oral carcinoma cell lines were recognized by Vγ9Vδ2 T cells via specific ligand/ receptor interactions. Zoledronate-treated oral carcinomas triggered cytokine production of Vγ9Vδ2 T cells. In addition, co-culturing zoledronate treated oral carcinomas and Vγ9Vδ2 T cells resulted in effective tumor cell lysis. Our findings could contribute to the development of novel immunotherapy for oral carcinomas.
|
